NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA ...
Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –– Pivotal Phase 3 trials in ...
Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, ...
Ikarovec Ltd, which is developing dual-pathway gene therapies for vision-threatening retinal diseases, and VectorBuilder, a ...
MedPage Today on MSN
Contaminated Water Blamed for 10 Deaths; Trump on Too Much Aspirin? FDA Rejections
Contaminated drinking water in Indore, India, was linked to 10 deaths and more than 270 hospitalizations, according to ...
Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize as ...
Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets - - Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 ...
Find out how higher dose aflibercept may reduce injection burden while preserving vision in retinal vasculopathy.
The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...
Ophthalmologists recognized at the ‘Surgical Strike 360’ conference in Chennai, showcasing innovative techniques and ...
Outlook Therapeutics faces a pivotal FDA decision for Lytenava on December 31st, following two prior rejections. Read why ...
The top read ophthalmology articles of 2025 focused on a variety of topics within the field, including links between ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback